Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

RedHill Biopharma

Nasdaq:RDHL
Snowflake Description

Excellent balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
RDHL
Nasdaq
$215M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of clinical late-stage drugs for the treatment of gastrointestinal diseases in the United States. The last earnings update was 35 days ago. More info.


Add to Portfolio Compare Print
  • RedHill Biopharma has significant price volatility in the past 3 months.
RDHL Share Price and Events
7 Day Returns
32.6%
NasdaqGM:RDHL
4.6%
US Pharmaceuticals
2.4%
US Market
1 Year Returns
-29.2%
NasdaqGM:RDHL
-2%
US Pharmaceuticals
-10%
US Market
RDHL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
RedHill Biopharma (RDHL) 32.6% 44.6% 1.2% -29.2% -39.7% -57.3%
US Pharmaceuticals 4.6% -3.1% -7.9% -2% 10% 5.4%
US Market 2.4% -11% -19.4% -10% 9.6% 21.1%
1 Year Return vs Industry and Market
  • RDHL underperformed the Pharmaceuticals industry which returned -2% over the past year.
  • RDHL underperformed the Market in United States of America which returned -10% over the past year.
Price Volatility
RDHL
Industry
5yr Volatility vs Market

RDHL Value

 Is RedHill Biopharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of RedHill Biopharma to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for RedHill Biopharma.

NasdaqGM:RDHL Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.8%
Perpetual Growth Rate 10-Year US Government Bond Rate 1.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:RDHL
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 1.7%
Equity Risk Premium S&P Global 6.3%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.63
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.629 (1 + (1- 23%) (1.77%))
0.757
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.74% + (0.8 * 6.33%)
6.8%

Discounted Cash Flow Calculation for NasdaqGM:RDHL using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for RedHill Biopharma is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqGM:RDHL DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 6.8%)
2020 -48.00 Analyst x1 -44.94
2021 60.00 Analyst x1 52.60
2022 85.68 Est @ 42.8% 70.33
2023 111.80 Est @ 30.49% 85.92
2024 136.25 Est @ 21.86% 98.04
2025 157.81 Est @ 15.83% 106.32
2026 176.11 Est @ 11.6% 111.09
2027 191.33 Est @ 8.64% 113.00
2028 203.90 Est @ 6.57% 112.76
2029 214.35 Est @ 5.12% 110.98
Present value of next 10 years cash flows $816.00
NasdaqGM:RDHL DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $214.35 × (1 + 1.74%) ÷ (6.8% – 1.74%)
$4,306.41
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $4,306.41 ÷ (1 + 6.8%)10
$2,229.67
NasdaqGM:RDHL Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $816.00 + $2,229.67
$3,045.67
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $3,045.67 / 35.27
$86.35
NasdaqGM:RDHL Discount to Share Price
Calculation Result
Value per share (USD) From above. $86.35
Current discount Discount to share price of $6.10
= -1 x ($6.10 - $86.35) / $86.35
92.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price RedHill Biopharma is available for.
Intrinsic value
>50%
Share price is $6.1 vs Future cash flow value of $86.35
Current Discount Checks
For RedHill Biopharma to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • RedHill Biopharma's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • RedHill Biopharma's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for RedHill Biopharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are RedHill Biopharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:RDHL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.42
NasdaqGM:RDHL Share Price ** NasdaqGM (2020-04-07) in USD $6.1
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 24 Publicly-Listed Pharmaceuticals Companies 20.33x
United States of America Market PE Ratio Median Figure of 2,948 Publicly-Listed Companies 12.95x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of RedHill Biopharma.

NasdaqGM:RDHL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:RDHL Share Price ÷ EPS (both in USD)

= 6.1 ÷ -1.42

-4.28x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • RedHill Biopharma is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • RedHill Biopharma is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does RedHill Biopharma's expected growth come at a high price?
Raw Data
NasdaqGM:RDHL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.28x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
88.4%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.91x
United States of America Market PEG Ratio Median Figure of 2,010 Publicly-Listed Companies 0.92x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for RedHill Biopharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on RedHill Biopharma's assets?
Raw Data
NasdaqGM:RDHL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $1.70
NasdaqGM:RDHL Share Price * NasdaqGM (2020-04-07) in USD $6.1
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 181 Publicly-Listed Pharmaceuticals Companies 2.42x
United States of America Market PB Ratio Median Figure of 5,162 Publicly-Listed Companies 1.26x
NasdaqGM:RDHL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:RDHL Share Price ÷ Book Value per Share (both in USD)

= 6.1 ÷ 1.70

3.59x

* Primary Listing of RedHill Biopharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • RedHill Biopharma is overvalued based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess RedHill Biopharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. RedHill Biopharma has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

RDHL Future Performance

 How is RedHill Biopharma expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
88.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is RedHill Biopharma expected to grow at an attractive rate?
  • RedHill Biopharma's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • RedHill Biopharma's earnings growth is expected to exceed the United States of America market average.
  • RedHill Biopharma's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:RDHL Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:RDHL Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 88.4%
NasdaqGM:RDHL Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 64.7%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 27.3%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:RDHL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:RDHL Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 321 187 127 2
2021-12-31 173 31 20 4
2020-12-31 98 -37 -27 5
2020-04-08
NasdaqGM:RDHL Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 6 -41 -42
2019-09-30 6 -35 -38
2019-06-30 7 -35 -39
2019-03-31 8 -32 -39
2018-12-31 8 -34 -39
2018-09-30 9 -40 -42
2018-06-30 8 -43 -47
2018-03-31 6 -44 -47
2017-12-31 4 -45 -46
2017-09-30 2 -41 -43
2017-06-30 1 -38 -37
2017-03-31 0 -34 -32

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • RedHill Biopharma's earnings are expected to grow significantly at over 20% yearly.
  • RedHill Biopharma's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:RDHL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from RedHill Biopharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:RDHL Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31 3.26 5.76 0.75 2.00
2021-12-31 0.51 1.96 0.00 4.00
2020-12-31 -0.54 -0.03 -1.12 5.00
2020-04-08
NasdaqGM:RDHL Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.42
2019-09-30 -1.37
2019-06-30 -1.45
2019-03-31 -1.56
2018-12-31 -1.68
2018-09-30 -1.94
2018-06-30 -2.37
2018-03-31 -2.50
2017-12-31 -2.58
2017-09-30 -2.70
2017-06-30 -2.46
2017-03-31 -2.33

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if RedHill Biopharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess RedHill Biopharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
RedHill Biopharma has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

RDHL Past Performance

  How has RedHill Biopharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare RedHill Biopharma's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • RedHill Biopharma does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare RedHill Biopharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare RedHill Biopharma's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
RedHill Biopharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from RedHill Biopharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:RDHL Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 6.29 -42.30 29.81 17.42
2019-09-30 6.06 -38.30 24.56 18.32
2019-06-30 6.87 -38.55 21.47 22.15
2019-03-31 7.65 -38.76 20.06 23.82
2018-12-31 8.36 -38.82 19.99 24.86
2018-09-30 9.00 -41.55 21.31 27.38
2018-06-30 8.32 -46.98 23.04 28.86
2018-03-31 6.45 -46.88 23.21 31.25
2017-12-31 4.01 -45.54 20.04 32.97
2017-09-30 2.11 -43.48 15.28 32.17
2017-06-30 0.58 -36.91 10.25 31.11
2017-03-31 0.10 -32.44 6.10 28.70
2016-12-31 0.10 -29.37 5.40 25.24
2016-09-30 0.00 -27.58 5.52 22.70
2016-06-30 0.00 -21.93 4.80 19.56
2016-03-31 0.00 -21.97 4.43 18.62
2015-12-31 0.00 -21.09 4.13 17.77
2015-09-30 0.00 -19.86 3.53 16.52
2015-06-30 0.01 -20.80 3.75 16.73
2015-03-31 0.01 -18.73 3.91 14.79
2014-12-31 7.01 -10.71 4.01 12.70
2014-09-30 7.01 -8.82 3.82 11.56
2014-06-30 7.01 -7.29 3.45 9.67
2014-03-31 7.01 -5.27 3.04 8.49
2013-12-31 0.01 -10.63 2.68 8.10
2013-09-30 0.02 -10.54 2.64 6.78
2013-06-30 0.02 -9.81 2.64 5.96

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if RedHill Biopharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if RedHill Biopharma has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if RedHill Biopharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess RedHill Biopharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
RedHill Biopharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

RDHL Health

 How is RedHill Biopharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up RedHill Biopharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • RedHill Biopharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • RedHill Biopharma's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of RedHill Biopharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • RedHill Biopharma has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from RedHill Biopharma Company Filings, last reported 3 months ago.

NasdaqGM:RDHL Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 60.00 0.00 47.87
2019-09-30 22.85 0.00 25.65
2019-06-30 31.90 0.00 34.87
2019-03-31 41.88 0.00 45.53
2018-12-31 51.19 0.00 53.19
2018-09-30 39.84 0.00 43.03
2018-06-30 25.91 0.00 27.90
2018-03-31 36.29 0.00 36.35
2017-12-31 45.07 0.00 46.21
2017-09-30 33.96 0.00 39.44
2017-06-30 48.80 0.00 51.07
2017-03-31 58.95 0.00 60.58
2016-12-31 62.70 0.00 66.15
2016-09-30 40.49 0.00 40.50
2016-06-30 48.98 0.00 47.73
2016-03-31 54.94 0.00 53.28
2015-12-31 60.08 0.00 58.14
2015-09-30 66.19 0.00 64.14
2015-06-30 27.62 0.00 26.48
2015-03-31 33.89 0.00 32.53
2014-12-31 25.01 0.00 22.95
2014-09-30 29.94 0.00 29.05
2014-06-30 33.68 0.00 24.17
2014-03-31 37.05 0.00 37.67
2013-12-31 11.93 0.00 12.11
2013-09-30 14.29 0.00 13.71
2013-06-30 15.26 0.00 14.70
  • RedHill Biopharma has no debt.
  • RedHill Biopharma has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • RedHill Biopharma has sufficient cash runway for 1.2 years based on current free cash flow.
  • RedHill Biopharma has less than a year of cash runway if free cash flow continues to grow at historical rates of 22.5% each year.
X
Financial health checks
We assess RedHill Biopharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. RedHill Biopharma has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

RDHL Dividends

 What is RedHill Biopharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from RedHill Biopharma dividends. Estimated to be 0% next year.
If you bought $2,000 of RedHill Biopharma shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate RedHill Biopharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate RedHill Biopharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:RDHL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 2.9%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1935 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:RDHL Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31 0.00 1.00
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as RedHill Biopharma has not reported any payouts.
  • Unable to verify if RedHill Biopharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of RedHill Biopharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as RedHill Biopharma has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of RedHill Biopharma's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess RedHill Biopharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can RedHill Biopharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. RedHill Biopharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

RDHL Management

 What is the CEO of RedHill Biopharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Dror Ben-Asher
COMPENSATION $707,922
AGE 53
TENURE AS CEO 10.7 years
CEO Bio

Mr. Dror Ben-Asher Co-Founded RedHill Biopharma Ltd. and has been its Chief Executive Officer since August 3, 2009. Mr. Ben-Asher serves as an Associate of Mercator Group, LLC. He has been affiliated with The Mercator Group since 1999. Mr. Ben-Asher has worked with Mercator on several projects including EquipNet, eCapitaledge.com, Tefron, Ltd. and Internet Media Group. He has extensive managerial and transactional expertise, He was with ProSeed Capital, a European corporate finance boutique. He was a Co-Founder of ProSeed Capital Holdings CVA and served as its President and Chief Executive Officer. He served as a Manager at P.C.M.I. Ltd., an affiliate of ProSeed Capital Holdings CVA from January 2002 to November 2010. He was a Co-Founder of ProSeed Venture I, L.P. and served as its President and Co-Chief Executive Officer. He served as a Consultant for a leading Israeli law firm and the Harvard International Law Journal at Harvard Law School. He served as an Officer in the Israeli Defense Forces. Mr. Ben-Asher has been the Chairman of RedHill Biopharma Ltd. since May 4, 2011 and has been its director since August 3, 2009. He serves as a Director of Agrea Ltd. He served as Director of ProSeed Venture I, L.P. He is writing his doctoral thesis at Harvard Law School. He concentrates on the pharmaceutical and medical devices industries and antitrust issues. He has a number of publications and teaches sections of graduates at Harvard Law School and undergraduates at Harvard's Economics department. At Harvard, he was a Fulbright Scholar focusing on the pharmaceutical industry and markets. He speaks fluent Hebrew and English and has some knowledge of Spanish. He is an Olin Fellow for Law, Economics and Business and an Economics Teaching Fellow at Harvard. He received his LL.B. with distinction (First Class Honours) from the University of Leicester. He is a graduate of the University of Oxford (M.Jur.). As an Oxford scholar, he received a Masters degree in European and Comparative Law from Oxford University, specializing in European business law, intellectual property and competition law. Mr. Ben-Asher completed LLM studies at Harvard University in the U.S.

CEO Compensation
  • Dror's compensation has increased whilst company is loss making.
  • Dror's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the RedHill Biopharma management team in years:

4.1
Average Tenure
50
Average Age
  • The tenure for the RedHill Biopharma management team is about average.
Management Team

Dror Ben-Asher

TITLE
Co-Founder
COMPENSATION
$708K
AGE
53
TENURE
10.7 yrs

Micha Ben-Chorin

TITLE
Chief Financial Officer
COMPENSATION
$506K
AGE
50
TENURE
4.1 yrs

Gilead Raday

TITLE
Chief Operating Officer
COMPENSATION
$539K
AGE
44
TENURE
4 yrs

Adi Frish

TITLE
Senior Vice President of Business Development & Licensing
COMPENSATION
$505K
AGE
49
TENURE
7.3 yrs

Guy Goldberg

TITLE
Chief Business Officer
COMPENSATION
$505K
AGE
43
TENURE
7.8 yrs

June Almenoff

TITLE
Chief Scientific Officer
AGE
62
TENURE
0.9 yrs

Shani Maurice

TITLE
Vice President of Business Development & Communications
TENURE
3.9 yrs

Val Graceffa

TITLE
Vice President of Sales

Rob Jackson

TITLE
Vice President of Marketing
TENURE
0.9 yrs

Reza Fathi

TITLE
Senior Vice President of Research & Development
COMPENSATION
$420K
AGE
64
TENURE
9.9 yrs
Board of Directors Tenure

Average tenure and age of the RedHill Biopharma board of directors in years:

8.9
Average Tenure
62
Average Age
  • The tenure for the RedHill Biopharma board of directors is about average.
Board of Directors

Rick Scruggs

TITLE
Chief Commercial Officer & Director
AGE
59
TENURE
4.3 yrs

Eric Swenden

TITLE
Director
AGE
75
TENURE
9.9 yrs

Dror Ben-Asher

TITLE
Co-Founder
COMPENSATION
$708K
AGE
53
TENURE
8.9 yrs

Ofer Tsimchi

TITLE
External Director
AGE
59
TENURE
8.9 yrs

Jeff Leighton

TITLE
Chairman of Advisory Board
AGE
73

Ira Kalfus

TITLE
Member of Advisory Board
AGE
58
TENURE
1.3 yrs

Ken Reed

TITLE
Director
AGE
65
TENURE
10.3 yrs

Shmuel Cabilly

TITLE
Director
AGE
69
TENURE
0.6 yrs

Ran Oren

TITLE
Member of Advisory Board

Chezy Barenholz

TITLE
Member of Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess RedHill Biopharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. RedHill Biopharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

RDHL News

Simply Wall St News

RDHL Company Info

Description

RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of clinical late-stage drugs for the treatment of gastrointestinal diseases in the United States. The company commercializes and promotes various gastrointestinal products, including Donnatal, a prescription oral adjunctive drug used in the treatment of irritable bowel syndrome (IBS) and acute enterocolitis; EnteraGam, a medical food for the dietary management of chronic diarrhea and loose stools; and Mytesi, an anti-diarrheal drug for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy. Its principal clinical late-stage development programs include Talicia for the treatment and eradication of Helicobacter pylori infection for which an NDA submitted and accepted for priority review; RHB-104 with positive results from a first Phase 3 study for crohn's disease; RHB-204, a planned pivotal Phase 3 study drug for pulmonary nontuberculous mycobacteria infections; BEKINDA with positive results from a first Phase 3 study for acute gastroenteritis and gastritis, as well as from a Phase 2 study for IBS with diarrhea; YELIVA, a selective inhibitor for multiple oncology, inflammatory, and gastrointestinal indications with an ongoing Phase 2a studies for cholangiocarcinoma; RHB-106, an encapsulated bowel preparation; and RHB-107, a Phase 2-stage serine protease inhibitor for cancer and inflammatory gastrointestinal diseases. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.

Details
Name: RedHill Biopharma Ltd.
RDHL
Exchange: NasdaqGM
Founded: 2009
$215,144,352
35,269,566
Website: http://www.redhillbio.com
Address: RedHill Biopharma Ltd.
21 Ha’arba’a Street,
Tel Aviv,
6473921,
Israel
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM RDHL SPONSORED ADS Nasdaq Global Market US USD 27. Dec 2012
DB 2RH SPONSORED ADS Deutsche Boerse AG DE EUR 27. Dec 2012
OTCPK REDI.F Ordinary Shares Pink Sheets LLC US USD 17. Feb 2011
Number of employees
Current staff
Staff numbers
155
RedHill Biopharma employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 03:46
End of day share price update: 2020/04/07 00:00
Last estimates confirmation: 2020/03/28
Last earnings filing: 2020/03/04
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.